GlaxoSmithKline (GSK), a UK-listed drugs company, has set aside £50m ($78m) to launch a corporate venturing fund for the country’s early-stage healthcare companies and spin-outs from universities. The UK Venture Capital Fund will be part of GSK’s existing corporate venturing unit, SR One, and is similar in scope to semiconductor company Intel’s launch of regional…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
